Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns $10M Biogen Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns $10M Biogen Milestone

Validates undisclosed target to treat a neurological disorder

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. This is the ninth program to advance under the strategic alliance, which includes four drugs in development to treat neurological and neuromuscular disorders. To date, Isis has earned $329 million in payments from Biogen. 
 
“Together with Biogen, we have made significant progress advancing multiple programs.  In our pipeline, we have four drugs in development with Biogen, including ISIS-SMNRx, ISIS-DMPK-2.5Rx and two drugs to undisclosed targets.  In addition, we have a number of earlier stage programs, like this one, that we will be advancing this year,” said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics